Overview
The LYNX study is a 2-part, multicenter, Phase 2 study of safety, pharmacokinetics and biomarkers in children with Duchenne muscular dystrophy including a randomized, double-blind, placebo-controlled part A, followed by an open-label part B.
Description
The EDG-5506-210 protocol was amended to include an additional dose cohort and a cohort to include participants not currently treated with corticosteroids.
This is a 2-part, multi-center, Phase 2 study to evaluate the effect of EDG-5506 on safety, pharmacokinetics and biomarkers of muscle damage in approximately 54 children with DMD treated with oral, once-daily EDG-5506 for 24 months. This study will have up to a 4-week Screening period, a 12-week randomized, double-blind, placebo controlled treatment period (Part A), a 92-week open-label extension period (Part B), and a 2-week follow up period.
Approximately 54 participants aged 4 to 9 years inclusive will be randomized to EDG-5506 or placebo in a 2:1 ratio. Five dose cohorts (C1, C2, C3, C4 and C5) of approximately 9 participants each will be enrolled sequentially.
An additional cohort, Cohort 2NS, to include participants (aged 4 to 7 years inclusive) not currently treated with corticosteroids, will enroll approximately 9 participants after Cohort 2 safety review and in parallel with the additional cohorts.
Eligibility
Key Common Inclusion Criteria:
- A documented mutation on the DMD gene and phenotype consistent with Duchenne muscular dystrophy.
- Able to complete the stand from supine in ≤ 10 seconds and able to perform the 4-stair climb in < 10 seconds at the Screening visit.
- Body weight greater than or equal to 15 kg and less than 35 kg at the Screening visit.
For Cohorts 1, 2, 3, 4 and 5:
Aged 4-9 years on a stable dose of corticosteroids for a minimum of 6 months prior to the
Baseline visit.
For Cohort 2 Non-Steroid (Cohort 2NS):
Aged 4-7 years not on corticosteroids within 6 months prior to the Baseline visit.
Key Common Exclusion Criteria:
1. Medical history or clinically significant physical exam/laboratory result that, in the
opinion of the investigator, would render the participant unsuitable for the study.
This includes venous access that would be too difficult to facilitate repeated blood
testing.
2. A forced vital capacity < 60% predicted at the Screening visit for those participants
who are > 8 years old at Screening.
3. A cardiac echocardiography showing left ventricular ejection < 45% at the Screening
visit.
4. Receipt of an investigational drug within 30 days or 5 half-lives (whichever is
longer) of the Screening visit in the present study.
5. Receipt of a stable dose of an approved exon-skipping therapy with a treatment
duration of less than 1 year prior to the Screening visit.
For Cohort 2 Non-Steroid (Cohort 2NS):
Receipt of oral corticosteroids for the treatment of Duchenne muscular dystrophy in the
previous 6 months. Participants will not be tapered off steroids for the purpose of this
study and oral corticosteroids for the treatment of Duchenne muscular dystrophy may be
initiated after the Week 16 visit.